COVID and hematology: special considerations regarding patient safety, gold standard therapies and safety for health care professionals

Garnica, Márcia; Maiolino, Ângelo

doi:10.1016/j.htct.2020.04.001

Cited by 9 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infectious diseases are not uncommon in hematology patients, especially among HSCT recipients; nevertheless, the COVID-19 pandemic has considerably changed the practices of hematologists worldwide. While rapidly and efficiently treating the patients remains the optimal goal, repeated pre-admission PCR testing, reinforced isolation, use of personal protective equipment, and have become a standard-of-care prior to any new hospitalization or aplasia- inducing treatment [7] .…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease

Alsuliman

Stocker

Wyngaert

et al. 2022

Current Research in Translational Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease

Alsuliman

Stocker

Wyngaert

et al. 2022

Current Research in Translational Medicine

View full text Add to dashboard Cite

“…4 In these patients, the probability of developing severe case of COVID-19 is higher than healthy individuals without comorbidities. 5 The latest evidence showed that the risk of COVID-19 infection in cancer patients was the same as that Asian J Oncol in the normal population; however, cancer patients seemed to get severe complications of COVID-19 infection especially if they have recently undergone cancer treatment. 6,7 To control the rapid spread of disease dissemination, public health measures are undertaken to decrease hospital visits and elective procedures.…”

Section: Introductionmentioning

confidence: 99%

Multiple Myeloma Management in COVID-19 Era

Kurniawan

Halim

Sutandyo

2021

ASJO

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020. The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic. The objective of this review is to know the current recommendation to manage MM in the COVID-19 era. Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search. It was conducted on May 18, 2020, using the keywords “multiple myeloma” AND “COVID-19” AND “Prevalence OR Impact OR treatment OR prophylactic.” The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available. Results A total of 124 articles were identified through the search strategy. The two reviewers screened titles and abstracts of all articles. Most articles were excluded because of ineligible to the criteria. Ultimately, 18 articles were included in the final evaluation. MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition. Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression. For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient’s goal. Several MM societies have published the recommendation regarding the special stage of MM. Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients. However, there is scarce of evidence to do the recommendation.

show abstract

“…4 In these patients, the probability of developing severe case of COVID-19 is higher than healthy individuals without comorbidities. 5 The latest evidence showed that the risk of COVID-19 infection in cancer patients was the same as that in the normal population; however, cancer patients seemed to get severe complications of COVID-19 infection especially if they have recently undergone cancer treatment. 6,7 To control the rapid spread of disease dissemination, public health measures are undertaken to decrease hospital visits and elective procedures.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2021

Asian Journal of Oncology

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020. The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic. The objective of this review is to know the current recommendation to manage MM in the COVID-19 era. Materials and Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search. It was conducted on May 18, 2020, using the keywords "multiple myeloma" AND "COVID-19" AND "Prevalence OR Impact OR treatment OR prophylactic." The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available. Results A total of 124 articles were identified through the search strategy. The two reviewers screened titles and abstracts of all articles. Most articles were excluded because of ineligible to the criteria. Ultimately, 18 articles were included in the final evaluation. MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition. Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression. For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient's goal. Several MM societies have published the recommendation regarding the special stage of MM. Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients. However, there is scarce of evidence to do the recommendation.

show abstract

COVID and hematology: special considerations regarding patient safety, gold standard therapies and safety for health care professionals

Cited by 9 publications

References 7 publications

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease

Multiple Myeloma Management in COVID-19 Era

Untitled

Contact Info

Product

Resources

About